• According to Transparency Market Research’s latest report on the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of cystic fibrosis and chronic pancreatitis to escalate the growth of global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market. Moreover, rising cases of diabetes are expected to fuel growth of the exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market
  • According to the report, the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market was valued at US$ 3.9 Bn in 2018 and is anticipated to expand at a CAGR of 7.2% from 2019 to 2027
new fa global exocrine pancreatic insufficiency

To know the scope of our report Get a Sample on Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

Rise in Focus on Research & Development and Surge in Number of People with Diabetes Mellitus: Key Drivers of Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

  • EPI is caused by insufficient secretion of pancreatic enzymes such as amylase, lipase, and protease and/ or sodium bicarbonate. Several disorders including different types of diabetes are associated with significantly increased risk for exocrine pancreatic insufficiency (EPI). For instance, according to an article published in Current Diabetes Reports, states that the prevalence of exocrine pancreatic insufficiency (EPI) is higher in type 1 diabetes than in type 2 diabetes. Thus, surge in number of people with diabetes is a key factor anticipated to drive the growth of exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market
  • Sedentary lifestyle and unhealthy diet are leading to surge in prevalence & incidence of diabetes. For instance, according to an article published in Diabetes Research and Clinical Practice, globally the prevalence of diabetes was 463 million in 2019 and is rising to 578 million by 2030
  • This is augmenting the demand for new treatment. To address these demands, the key players are investing in the research and development activities to develop and introduce new exocrine pancreatic insufficiency therapeutics thereby boosting the growth of market. For instance, AzurRx is developing a yeast-derived lipase, MS1819, which has been engineered to have superior enzymatic activity as compared to current treatments

Get a glimpse of the in-depth analysis through our Report Brochure

Increase in Prevalence of Chronic Pancreatitis and Cystic Fibrosis Propel Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Growth

  • Cystic fibrosis is the most common cause of exocrine pancreatic insufficiency. Around 50% of infants with cystic fibrosis have exocrine pancreatic insufficiency at birth, and another 25% develop it within six months. An additional 15% develop exocrine pancreatic insufficiency sometime in childhood or early adulthood.
  • Thus, rise in the global incidence of cystic fibrosis and chronic pancreatitis is one of the major factors driving the exocrine pancreatic insufficiency therapeutics & diagnostics market

Stringent FDA Regulations to Hamper Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

  • Pancreatic enzyme replacement therapy (PERT) using pancrelipase products, which are mostly purified from the porcine pancreas, has been tested widely for exocrine pancreatic insufficiency associated with pancreatic diseases. Pancreatic enzyme products have been available as over-the-counter drugs in many regions for several years.
  • However, some drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), have instructed that manufacturers obtain regulatory approvals before marketing their products because of possible adverse effects and inadequate effectiveness. These stringent FDA regulations have made approval of pancrelipase products difficult. This is leading to restrain the growth of market

Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market: Competitive Landscape

  • This report profiles major players in the global exocrine pancreatic insufficiency therapeutics & diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global exocrine pancreatic insufficiency therapeutics & diagnostics market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market
    • AbbVie, Inc
    • Allergan plc.
    • Nordmark Arzneimittel GmbH & Co. KG
    • Digestive Care, Inc.
    • Janssen Pharmaceuticals, Inc.
    • Cilian AG
    •  Anthera Pharmaceuticals, Inc
    • AzurRx Biopharma, Inc.

Expanding operations in future? To get the perfect launch ask for a custom report 

Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market: Key Developments

Key players in the global exocrine pancreatic insufficiency therapeutics & diagnostics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global exocrine pancreatic insufficiency therapeutics & diagnostics market. A few expansion strategies adopted by players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market are:

  • In April 2020, AzurRx Biopharma, Inc. has received Institutional Review Board (IRB) approval of its Phase 2 OPTION 2 clinical trial protocol to investigate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI)
  • In April 2020, AzurRx Biopharma, Inc. has entered into a manufacturing agreement with Delpharm for the clinical drug product supply of its MS1819 therapy for exocrine pancreatic insufficiency (EPI)
  • In February 2020, Vivus Inc. announced that the U.S. Food and Drug Administration has approved the supplemental New Drug Application (sNDA) for PANCREAZE. PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions

The report on the global exocrine pancreatic insufficiency therapeutics & diagnostics market discussed individual strategies, followed by company profiles of manufacturers of exocrine pancreatic insufficiency therapeutics. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market.

TMR’s report on the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market.

The report delves into the competitive landscape of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market. Key players operating in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market that have been profiled in this report.

Key Questions Answered in Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Report

  • What is the scope of growth for product companies in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market?
  • What will be the Y-o-Y growth of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market between 2019 and 2027?
  • What is the influence of changing trends in technologies on the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market?
  • Will North America continue to be the most profitable market for exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics providers?
  • Which factors are anticipated to hamper the growth of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market during the forecast period?
  • Which are the leading companies in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary research sources referred to by analysts during the production of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market as primary methods.

These primary research respondents have provided exclusive information during interviews, which serves as a validation from the exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics more reliably and accurately.

Regional Segmentation of Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market - Segmentation

Type

  • Therapeutics
  • Diagnostics
  • Blood Tests
  • Endoscopic Ultra-sonography (EUS)
  • Magnetic Resonance Imaging (MRI)
  • CT Scanning

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Exocrine Pancreatic Insufficiency

Buy Now